Todd A. Fehniger, M.D., Ph.D.

Peer-reviewed Articles

• Cai SF, Fehniger TA, Cao X, Mayer JC, Brune JD, French AR, Ley TJ
  Differential expression of granzyme B and C in murine cytotoxic lymphocytes.
  J Immunol 2009 May 15;182(10):6287-97
• Fehniger TA, Byrd JC, Marcucci G, Abboud CN, Kefauver C, Payton JE, Vij R, Blum W
  Single-agent lenalidomide induces complete remission of acute myeloid leukemia in patients with isolated trisomy 13.
  Blood 2009 Jan 29;113(5):1002-5
• Cao X, Cai SF, Fehniger TA, Song J, Collins LI, Piwnica-Worms DR, Ley TJ
  Granzyme B and perforin are important for regulatory T cell-mediated suppression of tumor clearance.
  Immunity 2007 Oct;27(4):635-46
• French AR, Kim S, Fehniger TA, Pratt JR, Yang L, Song YJ, Caligiuri MA, Yokoyama WM
  Chronic lymphocytosis of functionally immature natural killer cells.
  J Allergy Clin Immunol 2007 Oct;120(4):924-31
• Fehniger TA, Cai SF, Cao X, Bredemeyer AJ, Presti RM, French AR, Ley TJ
  Acquisition of murine NK cell cytotoxicity requires the translation of a pre-existing pool of granzyme B and perforin mRNAs.
  Immunity 2007 Jun;26(6):798-811
• Bredemeyer AJ, Carrigan PE, Fehniger TA, Smith DF, Ley TJ
  Hop cleavage and function in granzyme B-induced apoptosis.
  J Biol Chem 2006 Dec 1;281(48):37130-41
• Fehniger TA, Cooper MA, Nuovo GJ, Cella M, Facchetti F, Colonna M, Caligiuri MA
  CD56bright natural killer cells are present in human lymph nodes and are activated by T cell-derived IL-2: a potential new link between adaptive and innate immunity.
  Blood 2003 Apr 15;101(8):3052-7
• Farag SS, George SL, Lee EJ, Baer M, Dodge RK, Becknell B, Fehniger TA, Silverman LR, Crawford J, Bloomfield CD, Larson RA, Schiffer CA, Caligiuri MA
  Postremission therapy with low-dose interleukin 2 with or without intermediate pulse dose interleukin 2 therapy is well tolerated in elderly patients with acute myeloid leukemia: Cancer and Leukemia Group B study 9420.
  Clin Cancer Res 2002 Sep;8(9):2812-9
• Cooper MA, Bush JE, Fehniger TA, VanDeusen JB, Waite RE, Liu Y, Aguila HL, Caligiuri MA
  In vivo evidence for a dependence on interleukin 15 for survival of natural killer cells.
  Blood 2002 Nov 15;100(10):3633-8
• Farag SS, Fehniger TA, Ruggeri L, Velardi A, Caligiuri MA
  Natural killer cell receptors: new biology and insights into the graft-versus-leukemia effect.
  Blood 2002 Sep 15;100(6):1935-47
• Comella K, Nakamura M, Melnik K, Chosy J, Zborowski M, Cooper MA, Fehniger TA, Caligiuri MA, Chalmers JJ
  Effects of antibody concentration on the separation of human natural killer cells in a commercial immunomagnetic separation system.
  Cytometry 2001 Dec 1;45(4):285-93
• Cooper MA, Fehniger TA, Caligiuri MA
  The biology of human natural killer-cell subsets. [Review]
  Trends Immunol 2001 Nov;22(11):633-40
• Cooper MA*, Fehniger TA*, Turner SC, Chen KS, Ghaheri BA, Ghayur T, Carson WE, Caligiuri MA (*equal authorship)
  Human natural killer cells: a unique innate immunoregulatory role for the CD56(bright) subset.
  Blood 2001 May 15;97(10):3146-51
• Cooper MA, Fehniger TA, Ponnappan A, Mehta V, Wewers MD, Caligiuri MA
  Interleukin-1beta costimulates interferon-gamma production by human natural killer cells.
  Eur J Immunol 2001 Mar;31(3):792-801
• Fehniger TA, Caligiuri MA
  Interleukin 15: biology and relevance to human disease. [Review]
  Blood 2001 Jan 1;97(1):14-32
• Fehniger TA, Suzuki K, Ponnappan A, VanDeusen JB, Cooper MA, Florea SM, Freud AG, Robinson ML, Durbin J, Caligiuri MA
  Fatal leukemia in interleukin 15 transgenic mice follows early expansions in natural killer and memory phenotype CD8+ T cells.
  J Exp Med 2001 Jan 15;193(2):219-31
• Fehniger TA, Bluman EM, Porter MM, Mrozek E, Cooper MA, VanDeusen JB, Frankel SR, Stock W, Caligiuri MA
  Potential mechanisms of human natural killer cell expansion in vivo during low-dose IL-2 therapy.
  J Clin Invest 2000 Jul;106(1):117-24
• Fehniger TA, Yu H, Cooper MA, Suzuki K, Shah MH, Caligiuri MA
  Cutting edge: IL-15 costimulates the generalized Shwartzman reaction and innate immune IFN-gamma production in vivo.
  J Immunol 2000 Feb 15;164(4):1643-7
• Fehniger TA, Shah MH, Turner MJ, VanDeusen JB, Whitman SP, Cooper MA, Suzuki K, Wechser M, Goodsaid F, Caligiuri MA
  Differential cytokine and chemokine gene expression by human NK cells following activation with IL-18 or IL-15 in combination with IL-12: implications for the innate immune response.
  J Immunol 1999 Apr 15;162(8):4511-20
• Yu H*, Fehniger TA*, Fuchshuber P, Thiel KS, Vivier E, Carson WE, Caligiuri MA (*equal authorship)
  Flt3 ligand promotes the generation of a distinct CD34(+) human natural killer cell progenitor that responds to interleukin-15.
  Blood 1998 Nov 15;92(10):3647-57
• Fehniger TA, Herbein G, Yu H, Para MI, Bernstein ZP, O'Brien WA, Caligiuri MA
  Natural killer cells from HIV-1+ patients produce C-C chemokines and inhibit HIV-1 infection.
  J Immunol 1998 Dec 1;161(11):6433-8
• Meropol NJ, Barresi GM, Fehniger TA, Hitt J, Franklin M, Caligiuri MA
  Evaluation of natural killer cell expansion and activation in vivo with daily subcutaneous low-dose interleukin-2 plus periodic intermediate-dose pulsing.
  Cancer Immunol Immunother 1998 Aug;46(6):318-26
• Frey M, Packianathan NB, Fehniger TA, Ross ME, Wang WC, Stewart CC, Caligiuri MA, Evans SS
  Differential expression and function of L-selectin on CD56bright and CD56dim natural killer cell subsets.
  J Immunol 1998 Jul 1;161(1):400-8
• Khatri VP*, Fehniger TA*, Baiocchi RA, Yu F, Shah MH, Schiller DS, Gould M, Gazzinelli RT, Bernstein ZP, Caligiuri MA (*equal authorship)
  Ultra low dose interleukin-2 therapy promotes a type 1 cytokine profile in vivo in patients with AIDS and AIDS-associated malignancies.
  J Clin Invest 1998 Mar 15;101(6):1373-8
• Fehniger TA, Carson WE, Mrozek E, Caligiuri MA
  Stem cell factor enhances interleukin-2-mediated expansion of murine natural killer cells in vivo.
  Blood 1997 Nov 1;90(9):3647-53
• Carson WE, Fehniger TA, Caligiuri MA
  CD56bright natural killer cell subsets: characterization of distinct functional responses to interleukin-2 and the c-kit ligand.
  Eur J Immunol 1997 Feb;27(2):354-60
• Carson WE, Fehniger TA, Haldar S, Eckhert K, Lindemann MJ, Lai CF, Croce CM, Baumann H, Caligiuri MA
  A potential role for interleukin-15 in the regulation of human natural killer cell survival.
  J Clin Invest 1997 Mar 1;99(5):937-43